{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:50:07Z","timestamp":1791528607124,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40262-024-01417-9","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:02:47Z","timestamp":1726066967000},"page":"1327-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-2149","authenticated-orcid":false,"given":"Kelly M.","family":"Mahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Mesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun M.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan C.","family":"Goulooze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"1417_CR1","unstructured":"JESDUVROQ (Daprodustat). [package insert] Durham, NC: GlaxoSmithKline. 2023 [cited 08 July 2024]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216951s000lbl.pdf"},{"key":"1417_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","volume":"26","author":"DYH Yap","year":"2020","unstructured":"Yap DYH, McMahon LP, Hao C. Recommendations by the Asian pacific society of nephrology (apsn) on the appropriate use of hif-ph inhibitors. Nephrology. 2020;26:105\u201318.","journal-title":"Nephrology"},{"issue":"6","key":"1417_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1417_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.16011219","volume":"15","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15(8):1155\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1417_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","volume":"12","author":"AM Meadowcroft","year":"2019","unstructured":"Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139\u201348.","journal-title":"Clin Kidney J"},{"issue":"1","key":"1417_CR6","first-page":"T-041","volume":"45","author":"KM Mahar","year":"2018","unstructured":"Mahar KM, Johnson BM. Population Kinetic\/Pharmacodynamic (K\/PD) Analyses of Daprodustat (Prolyl Hydroxylase Inhibitor) in Non-dialysis (ND) and Hemodialysis-Dependent (HDD) Anemia Patients with Chronic Kidney Disease (CKD). J Pharmacokinet Pharmacodyn. 2018;45(1):T-041.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1417_CR7","doi-asserted-by":"publisher","first-page":"c27","DOI":"10.1159\/000328060","volume":"118","author":"R Mactier","year":"2011","unstructured":"Mactier R, Davies S, Dudley C, Harden P, Jones C, Kanagasundaram S, et al. Summary of the 5th edition of the renal association clinical practice guidelines (2009\u20132012). Nephron Clin Pract. 2011;118(1):c27\u201370.","journal-title":"Nephron Clin Pract"},{"issue":"S64","key":"1417_CR8","first-page":"T040","volume":"45","author":"K Mahar","year":"2018","unstructured":"Mahar K, Mills R, Goyal N. Population Pharmacokinetic (POP-PK) Analysis of Daprodustat (GSK1278863) and its Metabolites in Non-dialysis (ND) and Hemodialysis-Dependent (HDD) Anemia Patients with Chronic Kidney Disease (CKD). J Pharmacokinet Pharmacodyn. 2018;45(S64):T040.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1417_CR9","first-page":"PI-031","volume":"109","author":"T Post","year":"2021","unstructured":"Post T, Mahar K, Ashman M. Population pharmacokinetic analysis of daprodustat in healthy volunteers (HV), global phase 2 and Japanese phase 3 studies in chronic kidney disease patients with anemia following once daily (QD) or 3 times weekly (TIW) administration. Clin Pharm Ther. 2021;109:PI-031.","journal-title":"Clin Pharm Ther"},{"issue":"12","key":"1417_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/cpdd.1029","volume":"10","author":"KM Mahar","year":"2021","unstructured":"Mahar KM, Caltabiano S, Andrews S, Ramanjineyulu B, Chen L, Young G, et al. Clinical pharmacokinetics of daprodustat: results of an absorption, distribution, and excretion study with intravenous microtracer and concomitant oral doses for bioavailability determination. Clin Pharmacol Drug Dev. 2021;10(12):1419\u201331 (2021-12-01).","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1417_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/ckj\/sfz013","volume":"12","author":"S Caltabiano","year":"2019","unstructured":"Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019;12(5):693\u2013701.","journal-title":"Clin Kidney J"},{"issue":"6","key":"1417_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","volume":"30","author":"K Hara","year":"2015","unstructured":"Hara K, Takahashi N, Wakamatsu A, Caltabiano S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015;30(6):410\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"1417_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cpdd.83","volume":"3","author":"BM Johnson","year":"2014","unstructured":"Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clin Pharmacol Drug Dev. 2014;3(2):109\u201317.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1417_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/cpdd.1090","volume":"11","author":"KM Mahar","year":"2022","unstructured":"Mahar KM, Shaddinger BC, Ramanjineyulu B, Andrews S, Caltabiano S, Lindsay AC, Cobitz AR. Pharmacokinetics of daprodustat and metabolites in individuals with normal and impaired hepatic function. Clin Pharmacol Drug Dev. 2022;11(5):562\u201375.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"2","key":"1417_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.327","volume":"6","author":"S Caltabiano","year":"2018","unstructured":"Caltabiano S, Mahar KM, Lister K, Tenero D, Ravindranath R, Cizman B, Cobitz AR. The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects. Pharmacol Res Perspect. 2018;6(2):1\u20139.","journal-title":"Pharmacol Res Perspect"},{"key":"1417_CR16","unstructured":"Van den Berg P, Post T, Ahsman Mea. Population dose-response analysis of hemoglobin data from global phase 2 and Japanese phase 3 studies with daprodustat in chronic kidney disease patients with anemia following once daily (QD) or 3 times weekly (TIW) administration. Clin Pharmacol Ther. 2021;109."},{"key":"1417_CR17","volume-title":"Bioanalytic method validation guidance for industry","author":"Food and Drug Administration","year":"2018","unstructured":"Food and Drug Administration. Bioanalytic method validation guidance for industry. US Department of Health and Human Services; 2018."},{"issue":"8","key":"1417_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/cpdd.793","volume":"9","author":"M Yamada","year":"2020","unstructured":"Yamada M, Osamura M, Ogura H, Onoue T, Wakamatsu A, Numachi Y, et al. A single-dose, open-label, randomized, two-way crossover study in healthy Japanese participants to evaluate the bioequivalence and the food effect on the pharmacokinetics of daprodustat. Clin Pharmacol Drug Dev. 2020;9(8):978\u201384.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"4","key":"1417_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401\u201321.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1417_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2125.2007.02855.x","volume":"64","author":"T Lehr","year":"2007","unstructured":"Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer\u2019s disease. Br J Clin Pharmacol. 2007;64(1):36\u201348.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1417_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"1417_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part ii: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):538\u201356.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1417_CR23","unstructured":"Beal S, Boeckmann L, Bauer R, Sheiner L. NONMEM User\u2019s Guides. (1989\u20132009). 2009."},{"issue":"3","key":"1417_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357 (2005\/09\/01\/).","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1417_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85\u201394 (2004\/08\/01\/).","journal-title":"Comput Methods Programs Biomed"},{"key":"1417_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria. 2020."},{"issue":"8","key":"1417_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","volume":"4","author":"AW Dreisbach","year":"2008","unstructured":"Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065\u201374.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1417_CR28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/cpt.3215","volume":"115","author":"YA Bi","year":"2024","unstructured":"Bi YA, Jordan S, King-Ahmad A, West MA, Varma MVS. Mechanistic determinants of daprodustat drug-drug interactions and pharmacokinetics in hepatic dysfunction and chronic kidney disease: significance of OATP1B-CYP2C8 interplay. Clin Pharmacol Ther. 2024;115(6):1336\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1417_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02353487","volume":"24","author":"R Bruno","year":"1996","unstructured":"Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24(2):153\u201372.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5\u20136","key":"1417_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/A:1022972420004","volume":"29","author":"PO Gisleskog","year":"2002","unstructured":"Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29(5\u20136):473\u2013505.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1417_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","volume":"47","author":"AHP Chan Kwong","year":"2020","unstructured":"Chan Kwong AHP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47(5):431\u201346.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01417-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:05:52Z","timestamp":1727931952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01417-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01417-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"15 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical studies mentioned in this manuscript were funded by GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.M.M. and S.Y. are employees of GSK and hold GSK shares. T.M.P., S.C.G., and E.M. are consultants at LAP&P, the Netherlands.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing"}},{"value":"All studies were conducted in accordance with the US Code of Federal Regulations (CFR), Good Clinical Practice, 21 CFR Parts 50, 56, and 312, the ethical principles set forth in the Declaration of Helsinki, the International Conference on Harmonization guideline regarding Good Clinical Practice (E6 Consolidated Guidance, April 1996), and the ethical requirements referred to in the European Union Directive 2001\/20\/EC. The study protocols were approved by the institutional review boards or ethics committees of the study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Model code is available in Electronic Supplementary Materials","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to critically revising the manuscript for important intellectual content and approve the manuscript for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Please refer to GSK weblink to access GSK\u2019s data sharing policies and as applicable seek anonymised subject level data via the link .","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statemen"}}]}}